Drug Trial Radar · NCT02843581
Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer
Last checked: Nov 19, 2026Latest source record: Sep 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jul 1, 2016
Primary completion
Jul 1, 2017
Study completion Jul 1, 2019
Sponsor
- Lead sponsor
- Fuda Cancer Hospital, GuangzhouAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shenzhen Hank Bioengineering Institute
- First posted
- Jul 26, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced esophageal cancer.
Conditions
- Metastatic Esophageal Cancer
Interventions
CryosurgeryDevice
Argon-helium cryosurgical system
NK immunotherapyBiological
Nutral killer cell immunotherapy for more than 6 times
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relief degreeTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fuda cancer institute in Fuda cancer hospital
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.